What Moltek does

Moltek Sağlık Hizmetleri Üretim ve Pazarlama A.Ş. ("Moltek") is a privately held Turkish radiopharmaceutical manufacturer founded in 2007, headquartered in Istanbul (Kuriş Kule, Kartal) with production operations in the Gebze Organized Industrial Zone (Gebze-Kocaeli). The company began commercial radiopharmaceutical production in 2009 at a 2,000 m² GMP-compliant facility and now operates three cyclotrons (commissioned 2009, 2014, and 2015) producing diagnostic and therapeutic radiopharmaceuticals for nuclear medicine. Its diagnostic portfolio includes FDG-18F for PET imaging in oncology, cardiology and neurology, Ga-68 PSMA and Ga-68 DOTATATE for prostate and neuroendocrine tumor imaging, Ge-68/Ga-68 generators (GalliaPharm, IGG100), and cold kits (NephroMAG-3, PoltechMIBI) for renal and myocardial imaging; its therapeutic portfolio spans Lutetium-177, Yttrium-90, Actinium-225, Holmium-166 microspheres and Radium-223 for targeted cancer therapy.

The business model is vertically integrated across four service lines — radiopharmaceutical production, nuclear medicine center design and commissioning, cyclotron facility installation and maintenance, and licensed logistics for time-sensitive radioactive distribution under Nuclear Regulatory Authority (Nükleer Düzenleme Kurumu) oversight — combined with distribution of Eckert & Ziegler-manufactured medical devices (Modular-Lab PharmTracer, Modular-Lab eazy, Modular-Lab Analytic HPLC, MiniScanPRO) and Ge-68/Ga-68 generators. Customers are public and private hospitals in Turkey with nuclear medicine departments, served via direct enterprise field sales rather than broad marketing channels; revenue model streams are characterized as one-time licensing on product sales alongside professional, managed and technical services on facilities.

The company is privately held and in September 2021 received a significant private equity investment from Taxim Capital, a Turkish PE firm, with stated use of funds to strengthen Moltek's nuclear medicine position and accelerate growth in Turkey and internationally. Revenue, headcount, and ownership percentages are not publicly disclosed.

Name

Moltek

Legal name

Moltek Sağlık Hizmetleri Üretim ve Pazarlama A.Ş.

Website

https://moltek.com.tr

Company type

Private

Founded year

2007

Operating status

Operating

Short description

Moltek is a privately held Turkish pharmaceutical manufacturer founded in 2007 that produces diagnostic and therapeutic radiopharmaceuticals from three cyclotrons in Gebze-Kocaeli, distributing them and Eckert & Ziegler medical devices to public and private hospitals across Turkey.

Ownership category

akta.pro rank

Product category

Radiopharmaceuticals / Nuclear Medicine

NAICS

Pharmaceutical and Medicine Manufacturing (3254), In-Vitro Diagnostic Substance Manufacturing (325413), Irradiation Apparatus Manufacturing (334517)

SIC

Pharmaceutical Preparations (2834), In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

Radioisotope Production (Reactor/Cyclotron/Gamma) (HLAIAGAD)

akta.pro secondary industries

Medical Radioisotope Production (Reactor/Cyclotron, Mo-99/Tc-99m, I-131, Lu-177, etc.) (EUAKAIAA), Radiopharmaceutical Manufacturing & CDMO (Synthesis, GMP, Packaging, QA/QC) (EUAKAIAC), Nuclear Medicine Imaging Tracers & PET/SPECT Supply Chain (FDG, Ga-68, logistics/cold chain) (EUAKAIAE), Radiopharmaceutical CDMO & Manufacturing (GMP Fill-Finish) (HLAIAGAF)

Keywords

• Radiopharmaceutical manufacturing
• Nuclear medicine products
• PET imaging agents
• Therapeutic radiopharmaceuticals
• Cyclotron production services

Headquarters

HQ city

Gebze

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Supply Chain, Marketing or Sales

Revenue model

1. Radiopharmaceutical Products: Sale of radiopharmaceuticals for nuclear medicine imaging and therapy, including diagnostic agents (FDG, cold kits) and therapeutic precursors (Lu-177, Y-90, Ac-225, Ho-166, Ra-223)
2. Cyclotron Facility Services: New facility installation services for cyclotron centers including project planning, installation, commissioning, acceptance and quality control, training and licensing
3. Nuclear Medicine Center Services: Comprehensive services for hospital nuclear medicine clinics from project planning and construction to licensing and commissioning
4. Nuclear Medicine Logistics: Professional logistics services for delivery of radiopharmaceuticals to hospitals via land and air routes, adhering to Nuclear Regulatory Authority requirements
5. Technical Service & Maintenance: Technical service and maintenance for cyclotron facilities and equipment, including various brands and models

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

Moltek manufactures diagnostic and therapeutic radiopharmaceuticals at its GMP-certified production facility in Gebze, operating three cyclotrons to produce FDG-18F, Ga-68 PSMA, Ga-68 DOTATATE, Tc-99m cold kits, Lu-177, Y-90, Ac-225, Ho-166, and Ra-223 agents. It also distributes radiopharmacy synthesis and quality control devices from Eckert & Ziegler, and provides cyclotron facility installation, nuclear medicine center setup, and licensed radioactive-materials logistics to public and private hospitals across Turkey and neighboring countries.

Product overview

Moltek is a radiopharmaceutical company offering a comprehensive portfolio of diagnostic and therapeutic nuclear medicine products. The diagnostic portfolio includes FDG-18F for PET imaging across oncology, cardiology, and neurology applications; 68Ge/68Ga generators for cyclotron-independent Gallium-68 production; Ga-68 PSMA and Ga-68 DOTATATE for targeted PET imaging; and cold kits (NephroMAG-3, PoltechMIBI) for kidney and cardiac/oncology imaging. The therapeutic portfolio includes Lutetium-177, Yttrium-90, Actinium-225, Holmium-166, and Radium-223 based radiopharmaceuticals for targeted cancer therapy. Supporting these pharmaceuticals, Moltek distributes a range of medical devices including the Modular-Lab PharmTracer (fully automated synthesis system), Modular-Lab eazy (compact radiosynthesizer), Modular-Lab Analytic HPLC module, and MiniScanPRO (thin layer chromatography scanner) — all from Eckert & Ziegler Eurotope. Moltek provides related services including radiopharmaceutical production (operates three cyclotrons since 2009), nuclear medicine center design and operation, cyclotron facility installation and management, and logistics for radioactive medical products.

Differentiator

Problem solved

Functional benefit

Products and services

• MOLTEK FDG (Fluorodeoxyglucose-18F) Positron emission tomography (PET) radiopharmaceutical for imaging abnormal glucose metabolism, used in oncology for cancer diagnosis and staging, in cardiology for myocardial viability assessment, and in neurology for epileptogenic focus identification and Alzheimer's differential diagnosis. Targeted at hospitals and clinics with PET imaging capabilities.
• 68Ge/68Ga Generator (GalliaPharm & IGG100) Cyclotron-independent positron emitter generator producing Gallium-68 for PET imaging, available in 10-65 mCi activities; GalliaPharm is pharmaceutical-grade for clinical use and IGG100 is chemical-grade for research and development. Distributed under partnership with Eckert & Ziegler Isotope for hospitals and research centers.
• NephroMAG-3 (Mertiatide Kit) Cold kit radiopharmaceutical preparation; after reconstitution with sodium pertechnetate (99mTc), used to evaluate kidney function, morphology, perfusion, and urine output characterization for renal scintigraphy in hospitals.
• PoltechMIBI (99mTc-MIBI Kit) Cold kit for myocardial perfusion scintigraphy (cardiology), tumor imaging (oncology), and parathyroid adenoma localization (endocrinology) after 99mTc labeling. Targeted at hospitals with nuclear medicine departments.
• Ga-68 PSMA PET/CT imaging agent that binds to Prostate-Specific Membrane Antigen, used for prostate cancer diagnosis, metastasis detection, and recurrence identification; targeted at hospitals performing PET/CT imaging for prostate cancer.
• Ga-68 DOTATATE PET imaging agent labeled with Gallium-68 that binds to somatostatin receptors on neuroendocrine tumor cells, used for neuroendocrine tumor detection in hospitals with PET imaging capability.
• Lutetium-177 (177Lu) Chloride Solution Radioactive precursor for the treatment of neuroendocrine tumors, prostate tumors, and palliative therapy of bone metastases; requires labeling with appropriate peptides before therapeutic use. Supplied to hospitals performing radionuclide therapy.
• Holmium-166 (166Ho) Microspheres Radioactive microspheres for radioembolization (Selective Internal Radiation Therapy, SIRT) of primary and secondary liver tumors not suitable for surgical resection; supplied to interventional radiology and nuclear medicine departments of hospitals.
• Actinium-225 (225Ac) Alpha particle-emitting radiopharmaceutical precursor with anti-neoplastic activity for prostate and neuroendocrine tumor treatment; supplied to hospitals and centers performing targeted alpha therapy.
• Yttrium-90 (90Y) Chloride Solution Radioactive precursor for neuroendocrine and prostate tumor treatment, requiring labeling with appropriate peptides before patient use; supplied to hospitals performing radionuclide therapy.
• Radium-223 (223Ra) Alpha emitter indicated for treatment of castration-resistant prostate cancer with symptomatic bone metastases and no known visceral metastatic disease; supplied to hospitals and oncology centers.
• Modular-Lab PharmTracer Fully automated radiopharmacy synthesis system with disposable cassettes for routine production of 18F-, 11C-, 68Ga-, 111In-, 177Lu-, and 90Y-DOTA peptides; GMP/cGMP/GLP/GAMP 5 compliant, with remote control and automatic report generation. Distributed by Moltek from Eckert & Ziegler Eurotope to hospital radiopharmacies and nuclear medicine centers.
• Modular-Lab eazy Compact radiosynthesis system for routine production of radiometal compounds for theranostic tracers, with automatic pressure connections, validated sterile disposable cassettes, and GMP/GAMP 5 compliance. Distributed to hospital and research radiopharmacies in partnership with Eckert & Ziegler Eurotope.
• Modular-Lab Analitik HPLC Module Analytical HPLC module for quality control of PET tracers and beta-emitting radiopharmaceuticals; connects directly to Modular-Lab product family systems with pre-programmed analysis processes. Distributed by Moltek to radiopharmacy and quality control laboratories.
• MiniScanPRO GMP-compliant thin layer chromatography (TLC) scanner for quality control of 68Ga, 177Lu, 90Y, 18F, 99mTc, and 123I radioisotopes, supporting R&D applications and in-process analysis. Distributed by Moltek to nuclear medicine and radiopharmacy quality control laboratories.
• Cyclotron Facility Installation Services End-to-end project services for new cyclotron centers covering project planning, installation, commissioning, acceptance and quality control, training, and Nuclear Regulatory Authority licensing. Provided to hospitals and healthcare systems establishing new cyclotron-based nuclear medicine capacity.
• Cyclotron Facility Operation Management Operation management service for already-installed cyclotron facilities seeking a competent partner; Moltek's team runs end-to-end operational processes on behalf of the facility owner. Targeted at hospitals and clinics that have installed cyclotron infrastructure but lack the in-house expertise to operate it effectively.
• Technical Service & Maintenance Technical service and preventive/corrective maintenance for cyclotron facilities and equipment, including various brands and models beyond Moltek-installed systems. Provided to hospitals and nuclear medicine centers to ensure uptime of cyclotron infrastructure.
• Nuclear Medicine Center Services Comprehensive services for hospital nuclear medicine clinics covering project planning, construction, equipment installation, licensing, and commissioning to operational handover. Targeted at public and private hospitals building or upgrading nuclear medicine clinics.
• Radiopharmaceutical Logistics Service Professional, licensed logistics service delivering radiopharmaceuticals to public and private hospitals nationwide across Turkey via land and air routes, using trained personnel and complying with Nuclear Regulatory Authority regulations. Provided to hospitals requiring reliable, time-sensitive delivery of short-lived radioactive materials.

Named customers1 record

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Partnerships

Nine partnerships are on record, tiered core and minor.

• Eckert & Ziegler IsotopecoreTechnology or IntegrationDistributor of pharmaceutical grade GalliaPharm (Ge-68/Ga-68) generators and IGG100 research grade generators for cyclotron-independent Gallium-68 production
• Eckert & Ziegler EurotopecoreTechnology or IntegrationProvider of Modular-Lab synthesis systems (PharmTracer, eazy, Analytic HPLC) and MiniScanPRO quality control equipment for radiopharmaceutical production
• CMR (Cesium Mangement and Recovery)minorOthersPartner company in nuclear medicine equipment ecosystem
• IsotopiaminorChannel Partner/ Reseller/ DistributorPartner in radiopharmaceutical distribution network
• ItheranosticsminorChannel Partner/ Reseller/ DistributorPartner in radiopharmaceutical distribution network
• LemerminorOthersPartner company in nuclear medicine equipment ecosystem
• PolatomminorChannel Partner/ Reseller/ DistributorPartner in radiopharmaceutical distribution network
• RotopminorChannel Partner/ Reseller/ DistributorPartner in radiopharmaceutical distribution network
• TemaminorChannel Partner/ Reseller/ DistributorPartner in radiopharmaceutical distribution network

Scale indicators4 records

Recent moves8 records

Expansion highlights5 records

Broad incumbents

• GE HealthCare: Global medical imaging and nuclear medicine player offering radiopharmaceuticals (including through its PET radiopharma operations) alongside scanners, cyclotrons, and services. Comparable as a broader incumbent in nuclear medicine rather than a specialized pure-play.
• Siemens Healthineers (PETNET Solutions): Operates one of the largest PET radiopharma distribution networks globally through PETNET Solutions, producing FDG and other PET tracers for hospitals. Comparable business model and product overlap with Moltek's diagnostic PET portfolio, at much larger scale.
• Curium Pharma: Global leader in nuclear medicine, producing diagnostic and therapeutic radiopharmaceuticals across SPECT, PET, and therapy isotopes. Comparable product portfolio to Moltek (FDG, Lu-177, Mo-99/Tc-99m) but operating at global scale across multiple geographies.
• Bracco Imaging: Italian-headquartered global imaging agent and radiopharmaceutical company with diagnostic and therapeutic nuclear medicine offerings. Comparable in diagnostic imaging agents and increasingly in therapeutic isotopes, though part of a broader contrast-media portfolio.

Direct peers

• Polatom: Polish national laboratory producing a broad range of diagnostic and therapeutic radioisotopes (Mo-99, I-131, Lu-177, Sm-153). Comparable as a regional European radiopharmaceutical producer with overlapping isotope portfolio and a documented distribution partnership with Moltek.
• Cardinal Health (Nuclear & Pharmacy Services): Operates one of the largest radiopharmaceutical distribution networks in the United States, supplying unit-dose radiopharmaceuticals to hospitals. Comparable in the radiopharmacy and last-mile distribution model, though geographically distinct.
• Isotopia Molecular Imaging: Israel-based radiopharmaceutical CDMO and distributor producing Lu-177, Sm-153, and other therapeutic isotopes for oncology. Comparable as a focused regional radiopharma player with overlapping therapeutic isotope portfolio and an active distribution partnership with Moltek.
• Lantheus Holdings: US-listed radiopharmaceutical company focused on diagnostic imaging agents and now expanding into therapeutic radiopharmaceuticals. Overlaps directly with Moltek's diagnostic PET/SPECT portfolio and increasingly with the Lu-177 therapeutic pipeline.
• Eczacıbaşı-Monrol: Turkish radiopharmaceutical manufacturer and nuclear medicine services provider operating cyclotrons and distribution networks in Turkey. Directly comparable to Moltek in geography, product portfolio (FDG, Lu-177, Ga-68 generators), and customer base (public/private hospitals).

Emerging players

• IBA (Ion Beam Applications): Belgian manufacturer of cyclotrons and provider of radiopharma production solutions, including turnkey facility builds. Comparable in the cyclotron installation and nuclear medicine infrastructure services that Moltek provides, though IBA operates primarily as an equipment and solutions vendor.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/moltekmolekuler

Compliance8 records

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Moltek